Australien - engelsk - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: sorbitol; lactic acid; water for injections; sodium hydroxide - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - furosemide, quantity: 10 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections; mannitol; sodium hydroxide - frusemide high dosage formulations are intended exclusively for patients with severely impaired renal function. use under strict medical supervision only within a hospital setting (see dosage and administration). high doses of frusemide may be used as an adjuvant treatment of oliguria and in the promotion of diuresis in the treatment of oedema; in selected patients with acute renal failure, e.g. in the post-operative phase and in association with septic infections; in selected patients with chronic renal failure with fluid retention, both in the pre-dialysis phase and when dialysis has become unavoidable, especially in the presence of acute pulmonary oedema; in selected patients with the nephrotic syndrome with severe impairment of renal function, e.g. in chronic glomerular nephritis, lupus erythematosus and kimmelstiel-wilson syndrome. if diuresis is less than 2.5 l/day, dialysis has to be used.

Singapore - engelsk - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - amiodarone hcl - injection - 150 mg/3 ml - amiodarone hcl 150 mg/3 ml

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

juniper biologics pty ltd - palonosetron hydrochloride, quantity: 56 microgram/ml (equivalent: palonosetron, qty 50 microgram/ml) - injection, solution - excipient ingredients: sodium hydroxide; disodium edetate; hydrochloric acid; sodium citrate dihydrate; mannitol; water for injections; citric acid monohydrate - aloxi is indicated for: - prevention of nausea and vomiting induced by cytotoxic chemotherapy. - prevention of postoperative nausea and vomiting (ponv) for up to 24 hours following surgery.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 100 mg - injection, concentrated - excipient ingredients: hydrochloric acid; lactic acid; sodium hydroxide; water for injections; sorbitol - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 40 mg - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid; sorbitol; lactic acid - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

juniper biologics pty ltd - palonosetron hydrochloride, quantity: 56 microgram/ml (equivalent: palonosetron, qty 50 microgram/ml) - injection, solution - excipient ingredients: sodium hydroxide; disodium edetate; hydrochloric acid; sodium citrate dihydrate; mannitol; water for injections; citric acid monohydrate - aloxi is indicated for: - prevention of nausea and vomiting induced by cytotoxic chemotherapy. - prevention of postoperative nausea and vomiting (ponv) for up to 24 hours following surgery.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: sulfuric acid; mannitol; water for injections; sodium hydroxide - vincristine sulfate is indicated in acute leukaemia - current practices of cancer chemotherapy involve the simultaneous use of several agents. for enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. it is rarely possible to achieve equally good results with single agent treatment. thus vincristine sulfate is often chosen as part of polychemotherapy because of its unique clinical toxicity (neuropathy). see dosage and administration for possible increased toxicity when used in combination therapy. it has been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non-hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular and diffuse types), rhabdomyosarcoma, neuroblastoma, wilm's tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: water for injections; mannitol; sulfuric acid; sodium hydroxide - vincristine sulfate is indicated in acute leukaemia - current practices of cancer chemotherapy involve the simultaneous use of several agents. for enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. it is rarely possible to achieve equally good results with single agent treatment. thus vincristine sulfate is often chosen as part of polychemotherapy because of its unique clinical toxicity (neuropathy). see dosage and administration for possible increased toxicity when used in combination therapy. it has been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non-hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular and diffuse types), rhabdomyosarcoma, neuroblastoma, wilm's tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - oxytocin, quantity: 5 iu; ergometrine maleate, quantity: 0.5 mg - injection, solution - excipient ingredients: sodium chloride; maleic acid; water for injections; acetic acid; sodium acetate trihydrate; chlorobutanol hemihydrate - active management of the third stage of labour. prevention and treatment of post-partum haemorrhage associated with uterine atony.